SCHEMBL2489239

SCHEMBL2489239

OB(O)c1cnc(Cl)nc1OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 4/20 0.56
LIPE Q05469 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.44
ENPP2 Q13822 1/20 0.43
HPGD P15428 2/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
TSHR P16473 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
HRH4 Q9H3N8 3/20 0.39
MCL1 Q07820 1/20 0.39
BAK1 Q16611 1/20 0.39
PDE5A O76074 1/20 0.38
KDM4E B2RXH2 1/20 0.38
SLC6A4 P31645 2/20 0.38
CNR1 P21554 1/20 0.38
ACHE P22303 1/20 0.38
CNR2 P34972 1/20 0.38
HTR2A P28223 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2724131 0.84 LIPE (0.51) PIN1LIPEL3MBTL1HPGDALDH1A1
SCHEMBL9987642 0.80 PIN1 (0.59) PIN1L3MBTL1HPGDALDH1A1LMNA
SCHEMBL2487650 0.80 LIPE (0.48) LIPEL3MBTL1HPGDALDH1A1LMNA
SCHEMBL31514805 0.78 PIN1 (0.60) PIN1L3MBTL1HPGDALDH1A1LMNA
SCHEMBL30756269 0.77 PIN1 (0.59) PIN1L3MBTL1HPGDALDH1A1LMNA
SCHEMBL30683113 0.77 PIN1 (0.59) PIN1L3MBTL1HPGDALDH1A1LMNA
SCHEMBL10201397 0.77 PIN1 (0.59) PIN1L3MBTL1HPGDALDH1A1LMNA
SCHEMBL12423709 0.77 PIN1 (0.59) PIN1L3MBTL1HPGDALDH1A1LMNA
SCHEMBL4147395 0.77 SLC6A4 (0.52) PIN1LIPEL3MBTL1ENPP2HPGD
SCHEMBL29950975 0.77 SLC6A4 (0.52) PIN1LIPEL3MBTL1ENPP2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178547-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-05-15 US disclosed
CN-102256968-A Heterocyclic antiviral compounds HOFFMANN LA ROCHE 2011-11-23 CN disclosed
EP-2379534-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-10-26 EP disclosed
WO-2010072598-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-07-01 WO disclosed
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS STEINER SANDRA 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100158860-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS RFC1, RRP1B, RRBP1 PIN1 4004/4885LIPE 3490/4885L3MBTL1 2820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.